Table 1.
Baseline Characteristics According to Statin Exposure
|
No exposure (n=2 058 249) |
Statin exposure (n=2 058 249) |
Standardized difference | |
|---|---|---|---|
| Matching variables | |||
| Age, y | |||
| Mean (SD) | 68.65 (10.36) | 68.65 (10.36) | 0.00000 |
| Age categories, y | |||
| 40–59 | 395 018 (19.2) | 395 018 (19.2) | |
| 60–69 | 683 378 (33.2) | 683 378 (33.2) | |
| 70–79 | 660 264 (32.1) | 660 264 (32.1) | |
| ≥80 | 319 589 (15.5) | 319 589 (15.5) | |
| Sex | |||
| Men | 958 989 (46.6) | 958 989 (46.6) | 0.00000 |
| Women | 1 099 260 (53.4) | 1 099 260 (53.4) | |
| Residence area* | |||
| Auvergne‐Rhône‐Alpes | 213 640 (10.4) | 213 640 (10.4) | 0.00000 |
| Bourgogne‐Franche‐Comté | 98 693 (4.8) | 98 693 (4.8) | |
| Bretagne | 104 714 (5.1) | 104 714 (5.1) | |
| Centre‐Val de Loire | 95 625 (4.6) | 95 625 (4.6) | |
| Corse | 8697 (0.4) | 8697 (0.4) | |
| Grand Est | 192 826 (9.4) | 192 826 (9.4) | |
| Hauts‐de‐France | 234 718 (11.4) | 234 718 (11.4) | |
| Ile‐de‐France | 317 010 (15.4) | 317 010 (15.4) | |
| Normandie | 121 260 (5.9) | 121 260 (5.9) | |
| Nouvelle‐Aquitaine | 199 285 (9.7) | 199 285 (9.7) | |
| Occitanie | 164 959 (8.0) | 164 959 (8.0) | |
| Pays de la Loire | 125 184 (6.1) | 125 184 (6.1) | |
| Provence‐Alpes‐Côte d’Azur | 133 389 (6.5) | 133 389 (6.5) | |
| Overseas departments | 47 939 (2.3) | 47 939 (2.3) | |
| Overseas territories | 310 (0.0) | 310 (0.0) | |
| Hypertension | |||
| No | 1 198 186 (58.2) | 1 198 186 (58.2) | 0.00000 |
| Yes | 860 063 (41.8) | 860 063 (41.8) | |
| Diabetes | |||
| No | 1 364 924 (66.3) | 1 364 924 (66.3) | 0.00000 |
| Yes | 693 325 (33.7) | 693 325 (33.7) | |
| Chronic respiratory condition | |||
| No | 1 872 316 (91.0) | 1 872 316 (91.0) | 0.00000 |
| Yes | 185 933 (9.0) | 185 933 (9.0) | |
| Covariates | |||
| Social deprivation index (quintiles) | |||
| 1 (least deprived) | 343 795 (16.7) | 330 208 (16.0) | 0.05887 |
| 2 | 366 832 (17.8) | 364 376 (17.7) | |
| 3 | 393 467 (19.1) | 393 311 (19.1) | |
| 4 | 422 536 (20.5) | 428 084 (20.8) | |
| 5 (most deprived) | 449 430 (21.8) | 459 712 (22.3) | |
| Unknown | 82 189 (4.0) | 82 558 (4.0) | |
| Smoking‐related condition | |||
| No | 2 001 677 (97.3) | 1 975 967 (96.0) | 0.06923 |
| Yes | 56 572 (2.7) | 82 282 (4.0) | |
| Alcohol‐related condition | |||
| No | 2 025 242 (98.4) | 2 027 375 (98.5) | –0.00838 |
| Yes | 33 007 (1.6) | 30 874 (1.5) | |
| Obesity‐related condition | |||
| No | 2 015 058 (97.9) | 2 015 593 (97.9) | –0.00182 |
| Yes | 43 191 (2.1) | 42 656 (2.1) | |
| Liver failure | |||
| No | 2 030 710 (98.7) | 2 042 408 (99.2) | –0.05568 |
| Yes | 27 539 (1.3) | 15 841 (0.8) | |
| NSAID | |||
| No | 1 732 982 (84.2) | 1 719 946 (83.6) | 0.01722 |
| Yes | 325 267 (15.8) | 338 303 (16.4) | |
| Low‐dose aspirin | |||
| No | 1 827 030 (88.8) | 1 514 305 (73.6) | 0.39618 |
| Yes | 231 219 (11.2) | 543 944 (26.4) | |
| Antiplatelet agent | |||
| No | 2 042 260 (99.2) | 2 005 808 (97.5) | 0.13885 |
| Yes | 15 989 (0.8) | 52 441 (2.5) | |
| Heparin | |||
| No | 2 044 349 (99.3) | 2 045 508 (99.4) | –0.00702 |
| Yes | 13 900 (0.7) | 12 741 (0.6) | |
| Anticoagulant | |||
| No | 2 010 491 (97.7) | 1 999 837 (97.2) | 0.03266 |
| Yes | 47 758 (2.3) | 58 412 (2.8) | |
| Oral corticosteroid | |||
| No | 1 944 371 (94.5) | 1 948 469 (94.7) | –0.00878 |
| Yes | 113 878 (5.5) | 109 780 (5.3) | |
| Anxiolytic | |||
| No | 1 872 500 (91.0) | 1 823 368 (88.6) | 0.07887 |
| Yes | 185 749 (9.0) | 234 881 (11.4) | |
| Hypnotic | |||
| No | 1 975 317 (96.0) | 1 952 287 (94.9) | 0.05349 |
| Yes | 82 932 (4.0) | 105 962 (5.1) | |
| Antidepressant | |||
| No | 1 902 683 (92.4) | 1 847 672 (89.8) | 0.09399 |
| Yes | 155 566 (7.6) | 210 577 (10.2) | |
| Antipsychotic | |||
| No | 2 044 795 (99.3) | 2 040 905 (99.2) | 0.02193 |
| Yes | 13 454 (0.7) | 17 344 (0.8) | |
| Statin description | |||
| Type of statin | |||
| Atorvastatin | 827 752 (40.2) | ||
| Fluvastatin | 55 585 (2.7) | ||
| Pravastatin | 375 936 (18.3) | ||
| Rosuvastatin | 384 904 (18.7) | ||
| Simvastatin | 414 072 (20.1) | ||
| Statin intensity | |||
| Low | 431 167 (20.9) | ||
| Moderate | 1 496 809 (72.7) | ||
| High | 130 273 (6.3) | ||
| Statin intensity and its type | |||
| Low | |||
| Fluvastatin 20/40 | 34 713 (1.7) | ||
| Pravastatin 10/20 | 288 465 (14.0) | ||
| Simvastatin 10 | 107 989 (5.2) | ||
| Moderate | |||
| Atorvastatin 10/20 | 718 121 (34.9) | ||
| Fluvastatin 80 | 20 872 (1.0) | ||
| Pravastatin 40 | 87 471 (4.2) | ||
| Rosuvastatin 5/10 | 364 262 (17.7) | ||
| Simvastatin 20/40 | 306 083 (14.9) | ||
| High | |||
| Atorvastatin 40/80 | 109 631 (5.3) | ||
| Rosuvastatin 20 | 20 642 (1.0) | ||
*
Statin users and nonusers were matched for residence area defined at departmental level (101 French departments). For the purpose of the presentation, these departments were aggregated into 15 regions.